Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 in BRAF V600 Mutant Advanced NSCLC
NCT02109653Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Planned start Jun 2015; status: withdrawn.
02
Drugs
encorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02109653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109653.